PacBio Cuts Sequencing Costs 30% with Sub-$300 HiFi Genomes Shipping
PACB•PacBio has begun worldwide shipments of SPRQ-Nx chemistry and multi-use SMRT Cells for its Revio platform, reducing genome sequencing costs by 30% and setting list prices at $345 per HiFi genome with sub-$300 potential at scale. Enhanced DeepConsensus AI and expanded methylation models deliver higher accuracy, yield, and epigenetic insights from the same sequencing run.
1. Global Rollout and Cost Savings
PacBio has released SPRQ-Nx chemistry and multi-use SMRT Cells for its Revio platform, achieving a 30% cost reduction compared to prior chemistry and reducing per-genome list price to $345, with customers sequencing at scale able to reach sub-$300 per genome.
2. Enhanced AI Consensus and Methylation Calling
SPRQ-Nx paired with DeepConsensus updates—optimized by Google’s AlphaEvolve agent—and expanded 5mC, 6mA and new 5hmC models deliver measurable gains in sequencing accuracy, processing speed, and richer epigenetic data from each run.
3. Beta Testing Performance
In beta trials across 20 sites in Europe, Asia and North America covering over 1,400 runs, SPRQ-Nx demonstrated increased yield, reduced failure rates across diverse sample types and consistent high throughput for large-scale genomic workflows.
4. Platform Upgrades and Future Expansion
Existing Revio systems can access SPRQ-Nx via a software upgrade and new consumables, while PacBio plans to extend SPRQ-Nx chemistry and other improvements to its Vega benchtop system later in 2026, targeting population-scale and disease cohort studies.
